HC Wainwright Estimates MindWalk’s Q1 Earnings (NASDAQ:HYFT)

MindWalk Holdings Corp. (NASDAQ:HYFT) – Research analysts at HC Wainwright lowered their Q1 2027 earnings per share (EPS) estimates for MindWalk in a research note issued to investors on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk’s Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.17) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $0.01 EPS.

MindWalk (NASDAQ:HYFT) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.The business had revenue of $3.03 million during the quarter.

Several other equities analysts also recently commented on the stock. JonesTrading began coverage on shares of MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 target price on the stock. Wall Street Zen cut shares of MindWalk from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $5.00.

MindWalk Price Performance

Shares of HYFT opened at $1.36 on Monday. The stock has a market cap of $63.53 million, a price-to-earnings ratio of -6.18 and a beta of 0.83. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.72 and a current ratio of 2.80. MindWalk has a 1 year low of $0.99 and a 1 year high of $3.25. The firm’s 50 day moving average is $1.56.

Institutional Trading of MindWalk

A number of large investors have recently added to or reduced their stakes in HYFT. Renaissance Technologies LLC grew its holdings in shares of MindWalk by 8.4% in the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares in the last quarter. Bank of Montreal Can raised its stake in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after purchasing an additional 24,500 shares in the last quarter. Virtu Financial LLC bought a new position in MindWalk during the fourth quarter valued at $51,000. XTX Topco Ltd grew its stake in shares of MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after buying an additional 44,331 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in shares of MindWalk in the 4th quarter worth about $91,000. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.